{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-231903","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.746135+00:00","generated_at":"2026-05-17T04:37:27.160039+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biomea Fusion reports 52-week Phase II COVALENT-111 data: HbA1c reductions up to 1.5% in severe insulin-deficient T2D","bullets":["In severe insulin-deficient T2D patients (n=10), icovamenib achieved durable HbA1c reduction of 1.2% (p=0.01) through Week 52 after 12 weeks dosing.","Best result in Arm B (n=6): mean HbA1c reduction of 1.5% (p=0.01); no treatment-related serious adverse events.","In patients on GLP-1 therapy not at glycemic targets (n=11), icovamenib added 1.3% HbA1c reduction (p=0.05) sustained to Week 52.","Phase IIb trial (COVALENT-211) in severe insulin-deficient T2D expected to start Q4 2025; Phase II with GLP-1 (COVALENT-212) also Q4.","Food Effect Study (COVALENT-121) ongoing, expected completion by December 2025; oral GLP-1 RA (BMF-650) Phase I data anticipated H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-231903","json":"https://secwatch.observer/filing/0001193125-25-231903.json","markdown":"https://secwatch.observer/filing/0001193125-25-231903.md","text":"https://secwatch.observer/filing/0001193125-25-231903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525231903/0001193125-25-231903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312525231903/d79150d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:37:27.160039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}